Please login to the form below

Not currently logged in

FDA warns of safety concern with SGLT2 inhibitors

Some drugs have been linked to high levels of blood acids

Blood cellsThe US FDA has warned that drugs in the SGLT2 inhibitor class of diabetes therapies can cause a potentially serious side effect.

The class - which includes widely used products such as Invokana (canagliflozin) from Johnson & Johnson, Eli Lilly/Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca's Farxiga (canagliflozin) - has been linked to high levels of blood acids that could require hospitalisation.

The US regulator said doctors and patients should pay close attention for any signs of the condition - known as ketoacidosis - such as "difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness."

It has not yet decided whether any changes will be needed to the prescribing information, said the FDA, which has identified 20 cases of ketoacidosis in SGLT2 inhibitor-treated patients via its Adverse Event Reporting System (AERS).

Invokana was the first SGLT2 inhibitor to reach the market and leads the category in terms of sales, bringing in $278m in the first quarter of the year, three times its turnover in the same period of 2014.

Diabetes drugs have been on the FDA's safety watch list for years, in part because they are used by such as high number of people but also on the back of a series of health scares. 

Most recently, the agency recommended changes to the labelling of two products in another diabetes drug class, the DPP4 inhibitors - after data suggested a link to cardiovascular complications. 

In April, an FDA advisory committee voted that labelling for AZ's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin) should be amended to reflect an increase in the risk of hospitalisation for heart failure. 

At the moment the potential impact of the FDA advisory on the SGLT2 inhibitor class is hard to gauge, although analyst Tim Anderson of Bernstein suggested the link to ketoacidosis could lend additional momentum to the DPP-4 inhibitor class, which is led by Merck & Co's $6bn Januvia (sitagliptin) brand.

Januvia stands to gain the most from any shift in prescribing patterns, as recently reported data from the large-scale TECOS cardiovascular outcomes study seems to have given it a clean bill of health.

Article by
Phil Taylor

18th May 2015

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...